TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations
TAS6417/CLN-081 是一种泛突变选择性 EGFR 酪氨酸激酶抑制剂，具有针对临床相关 EGFR 突变的广谱临床前活性
期刊:Molecular Cancer Research
影响因子:4.1
doi:10.1158/1541-7786.MCR-19-0419
Hibiki Udagawa #, Shinichi Hasako #, Akihiro Ohashi, Rumi Fujioka, Yumi Hakozaki, Mikiko Shibuya, Naomi Abe, Toshiharu Komori, Tomonori Haruma, Miki Terasaka, Ryoto Fujita, Akihiro Hashimoto, Kaoru Funabashi, Hiroyuki Yasuda, Kazutaka Miyadera, Koichi Goto, Daniel B Costa, Susumu S Kobayashi
